Abaloparatide
Generic name: Abaloparatide
Brand names: Tymlos
Dosage form: subcutaneous solution (3120 mcg/1.56 mL)
Drug class:
Parathyroid hormone and analogs
Usage of Abaloparatide
Abaloparatide is used to treat osteoporosis in postmenopausal women who have a high risk of bone fracture.
Abaloparatide is also used to increase bone density in men with osteoporosis who are at high risk for bone fracture.
Abaloparatide is used to treat people who cannot use another treatment for osteoporosis or other treatments did not work well.
Abaloparatide may also be used for purposes not listed in this medication guide.
Abaloparatide side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Abaloparatide may cause serious side effects. Call your doctor at once if you have:
Common side effects of abaloparatide may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Abaloparatide
You should not use abaloparatide if you are allergic to it.
Abaloparatide is not for use in children or young adults whose bones are still growing.
Tell your doctor if you have ever had:
Abaloparatide has caused bone cancer (osteosarcoma) in animals but it is not known whether this would occur in people using this medicine. Talk with your doctor about your own risk.
Abaloparatide is for use only in women who can no longer get pregnant. It is not known whether abaloparatide will harm an unborn baby. Tell your doctor if you think you may be pregnant.
It may not be safe to breastfeed while using this medicine. Ask your doctor about any risk.
Relate drugs
How to use Abaloparatide
Usual Adult Dose for Osteoporosis:
Recommended dose: 80 mcg subcutaneously once a dayComments:-Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.Use(s): For the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy; in postmenopausal women with osteoporosis, this drug reduces the risk of vertebral fractures and nonvertebral fractures.Also used to increase bone density in men with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.
Warnings
Abaloparatide has caused bone cancer (osteosarcoma) in animals but it is not known whether this would occur in people using abaloparatide. Talk with your doctor about your own risk.
Call your doctor at once if you have bone pain, unusual body aches, or a lump or swelling under your skin.
Avoid smoking cigarettes or drinking alcohol. Smoking or heavy drinking can reduce your bone mineral density, making fractures more likely.
What other drugs will affect Abaloparatide
Other drugs may affect abaloparatide, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
Popular FAQ
Some animal studies have found that Tymlos is associated with an increase in the risk of osteosarcoma (a type of cancerous bone tumor). It is not known if this increased risk translates to humans; however, authorities have warned that Tymlos should not be given to people already at increased risk of osteosarcoma, including those with Paget's disease of the bone, pre-existing bone malignancies, prior radiation therapy, or hereditary disorders that increase their risk of osteosarcoma. Continue reading
Some animal studies have found that Tymlos is associated with an increase in the risk of osteosarcoma (a type of cancerous bone tumor). It is not known if this increased risk translates to humans; however, authorities have warned that Tymlos should not be given to people already at increased risk of osteosarcoma, including those with Paget's disease of the bone, pre-existing bone malignancies, prior radiation therapy, or hereditary disorders that increase their risk of osteosarcoma. Continue reading
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions